People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel mechanisms of action.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...

Nadia Haddad, a physician and medical director of BCH’s Department of Behavioral Health, said ketamine can have make a big difference even for people with treatment-resistant depression.

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...